C/EBPalpha Regulates Generation of C/EBPbeta Isoforms Through Activation of Specific Proteolytic Cleavage

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 1999 Feb 18

PMID 10022857

Citations 34

Authors

A L Welm

N A Timchenko

G J Darlington

Affiliations

Soon will be listed here.

Abstract

C/EBPalpha and C/EBPbeta are intronless genes that can produce several N-terminally truncated isoforms through the process of alternative translation initiation at downstream AUG codons. C/EBPbeta has been reported to produce four isoforms: full-length 38-kDa C/EBPbeta, 35-kDa LAP (liver-enriched transcriptional activator protein), 21-kDa LIP (liver-enriched transcriptional inhibitory protein), and a 14-kDa isoform. In this report, we investigated the mechanisms by which C/EBPbeta isoforms are generated in the liver and in cultured cells. Using an in vitro translation system, we found that LIP can be generated by two mechanisms: alternative translation and a novel mechanism-specific proteolytic cleavage of full-length C/EBPbeta. Studies of mice in which the C/EBPalpha gene had been deleted (C/EBPalpha-/-) showed that the regulation of C/EBPbeta proteolysis is dependent on C/EBPalpha. The induction of C/EBPalpha in cultured cells leads to induced cleavage of C/EBPbeta to generate the LIP isoform. We characterized the cleavage activity in mouse liver extracts and found that the proteolytic cleavage activity is specific to prenatal and newborn livers, is sensitive to chymostatin, and is completely abolished in C/EBPalpha-/- animals. The lack of cleavage activity in the livers of C/EBPalpha-/- mice correlates with the decreased levels of LIP in the livers of these animals. Analysis of LIP production during liver regeneration showed that, in this system, the transient induction of LIP is dependent on the third AUG codon and most likely involves translational control. We propose that there are two mechanisms by which C/EBPbeta isoforms might be generated in the liver and in cultured cells: one that is determined by translation and a second that involves C/EBPalpha-dependent, specific proteolytic cleavage of full-length C/EBPbeta. The latter mechanism implicates C/EBPalpha in the regulation of posttranslational generation of the dominant negative C/EBPbeta isoform, LIP.

Citing Articles

The Role of CYP3A in Health and Disease.

Klyushova L, Perepechaeva M, Grishanova A Biomedicines. 2022; 10(11).

PMID: 36359206 PMC: 9687714. DOI: 10.3390/biomedicines10112686.

The "Janus" Role of C/EBPs Family Members in Cancer Progression.

Tolomeo M, Grimaudo S Int J Mol Sci. 2020; 21(12).

PMID: 32560326 PMC: 7352866. DOI: 10.3390/ijms21124308.

Sulforaphene Suppresses Adipocyte Differentiation via Induction of Post-Translational Degradation of CCAAT/Enhancer Binding Protein Beta (C/EBPβ).

Yang H, Kang M, Hur G, Lee T, Park I, Seo S Nutrients. 2020; 12(3).

PMID: 32183002 PMC: 7146557. DOI: 10.3390/nu12030758.

C/EBPß Isoform Specific Gene Regulation: It's a Lot more Complicated than you Think!.

Spike A, Rosen J J Mammary Gland Biol Neoplasia. 2020; 25(1):1-12.

PMID: 32078094 PMC: 7694698. DOI: 10.1007/s10911-020-09444-5.

Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.

Noack K, Mahendrarajah N, Hennig D, Schmidt L, Grebien F, Hildebrand D Arch Toxicol. 2016; 91(5):2191-2208.

PMID: 27807597 PMC: 6063353. DOI: 10.1007/s00204-016-1878-5.

References

Diehl A, Michaelson P, Yang S . Selective induction of CCAAT/enhancer binding protein isoforms occurs during rat liver development. Gastroenterology. 1994; 106(6):1625-37. DOI: 10.1016/0016-5085(94)90420-0. View

Timchenko N, Darlington G . CCAAT/enhancer binding protein alpha (C/EBPalpha) is an important mediator of mouse C/EBPbeta protein isoform production. Hepatology. 1999; 29(2):597-601. DOI: 10.1002/hep.510290245. View

OBrien R, Lucas P, Yamasaki T, Noisin E, GRANNER D . Potential convergence of insulin and cAMP signal transduction systems at the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter through CCAAT/enhancer binding protein (C/EBP). J Biol Chem. 1994; 269(48):30419-28. View

Tanaka T, Akira S, Yoshida K, Umemoto M, Yoneda Y, Shirafuji N . Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell. 1995; 80(2):353-61. DOI: 10.1016/0092-8674(95)90418-2. View

Calkhoven C, Bouwman P, Snippe L, Ab G . Translation start site multiplicity of the CCAAT/enhancer binding protein alpha mRNA is dictated by a small 5' open reading frame. Nucleic Acids Res. 1994; 22(25):5540-7. PMC: 310114. DOI: 10.1093/nar/22.25.5540. View

Yeh W, Cao Z, Classon M, McKnight S . Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. Genes Dev. 1995; 9(2):168-81. DOI: 10.1101/gad.9.2.168. View

Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D . Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995; 14(9):1932-41. PMC: 398292. DOI: 10.1002/j.1460-2075.1995.tb07185.x. View

Wang N, Finegold M, Bradley A, Ou C, Abdelsayed S, Wilde M . Impaired energy homeostasis in C/EBP alpha knockout mice. Science. 1995; 269(5227):1108-12. DOI: 10.1126/science.7652557. View

Raught B, Liao W, Rosen J . Developmentally and hormonally regulated CCAAT/enhancer-binding protein isoforms influence beta-casein gene expression. Mol Endocrinol. 1995; 9(9):1223-32. DOI: 10.1210/mend.9.9.7491114. View

10.

Darlington G, Wang N, Hanson R . C/EBP alpha: a critical regulator of genes governing integrative metabolic processes. Curr Opin Genet Dev. 1995; 5(5):565-70. DOI: 10.1016/0959-437x(95)80024-7. View

11.

An M, Hsieh C, Reisner P, Rabek J, Scott S, Kuninger D . Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide-mediated acute-phase response. Mol Cell Biol. 1996; 16(5):2295-306. PMC: 231217. DOI: 10.1128/MCB.16.5.2295. View

12.

Timchenko N, Wilde M, Nakanishi M, Smith J, Darlington G . CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. Genes Dev. 1996; 10(7):804-15. DOI: 10.1101/gad.10.7.804. View

13.

Lee Y, Miau L, Chang C, Lee S . Transcriptional induction of the alpha-1 acid glycoprotein (AGP) gene by synergistic interaction of two alternative activator forms of AGP/enhancer-binding protein (C/EBP beta) and NF-kappaB or Nopp140. Mol Cell Biol. 1996; 16(8):4257-63. PMC: 231424. DOI: 10.1128/MCB.16.8.4257. View

14.

Raught B, Gingras A, James A, Medina D, Sonenberg N, Rosen J . Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial.... Cancer Res. 1996; 56(19):4382-6. View

15.

May M, Ghosh S . Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol. 1997; 8(2):63-73. DOI: 10.1006/scbi.1997.0057. View

16.

Sterneck E, Tessarollo L, Johnson P . An essential role for C/EBPbeta in female reproduction. Genes Dev. 1997; 11(17):2153-62. PMC: 275394. DOI: 10.1101/gad.11.17.2153. View

17.

Timchenko N, Harris T, Wilde M, Bilyeu T, Finegold M, Darlington G . CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol. 1997; 17(12):7353-61. PMC: 232591. DOI: 10.1128/MCB.17.12.7353. View

18.

Tanaka T, Yoshida N, Kishimoto T, Akira S . Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J. 1998; 16(24):7432-43. PMC: 1170343. DOI: 10.1093/emboj/16.24.7432. View

19.

Miyamoto S, Seufzer B, Shumway S . Novel IkappaB alpha proteolytic pathway in WEHI231 immature B cells. Mol Cell Biol. 1998; 18(1):19-29. PMC: 121444. DOI: 10.1128/MCB.18.1.19. View

20.

Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S . Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology. 1998; 198(1-3):35-49. DOI: 10.1016/s0171-2985(97)80025-3. View